kainos loboratories,inc Logo

kainos loboratories,inc

Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.

4556 | T

Overview

Corporate Details

ISIN(s):
JP3205650009
LEI:
Country:
Japan
Address:
文京区本郷二丁目38番18号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kainos Laboratories, Inc., founded in May 1975, is a company engaged in the research, development, manufacturing, and sale of clinical diagnostic products. It specializes in innovative clinical testing reagents, including biochemical and immunochemistry diagnostics, and also handles pharmaceuticals. The company's operations encompass the entire product lifecycle, from R&D to marketing, distribution, and import/export activities. Kainos Laboratories positions itself as a pioneer in its field, focused on creating innovative medical diagnostic tools for the healthcare industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 02:17
Registration Form
確認書
Japanese 8.1 KB
2025-11-06 02:16
Interim Report
半期報告書-第51期(2025/04/01-2026/03/31)
Japanese 157.7 KB
2025-06-20 03:02
Governance Information
内部統制報告書-第50期(2024/04/01-2025/03/31)
Japanese 21.9 KB
2025-06-20 03:00
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 02:59
Annual Report
有価証券報告書-第50期(2024/04/01-2025/03/31)
Japanese 710.6 KB
2025-06-20 02:56
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-11-06 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-06 01:38
Interim Report
半期報告書-第50期(2024/04/01-2025/03/31)
Japanese 160.1 KB
2024-06-21 03:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-21 03:06
Governance Information
内部統制報告書-第49期(2023/04/01-2024/03/31)
Japanese 21.1 KB
2024-06-21 03:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-21 03:02
Annual Report
有価証券報告書-第49期(2023/04/01-2024/03/31)
Japanese 704.8 KB
2024-02-02 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-02 01:38
Quarterly Report
四半期報告書-第49期第3四半期(2023/10/01-2023/12/31)
Japanese 135.5 KB
2023-11-02 02:27
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all kainos loboratories,inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for kainos loboratories,inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for kainos loboratories,inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.